Now live: Pro — the full 13F research suite for serious investorsSee pricing →
First Turn Management, LLC

Q1 2024 · 13F-HR

First Turn Management, LLCholdings as filed

Filed 2024-05-06 · accession 0001085146-24-002247

$668.5M
Reported value
34
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
82489T104SWAVUSDSHOCKWAVE MED INC$31.9M4.78%98,111CommonSOLE
04016X101ARGXARGENX SE$31.5M4.71%79,978CommonSOLE
23282W605CYTKCYTOKINETICS INC$30.2M4.51%430,349CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$29.3M4.38%680,389CommonSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$28.7M4.29%221,748CommonSOLE
05464T104AXSMAXSOME THERAPEUTICS INC$27.3M4.08%342,173CommonSOLE
252131107DXCMDEXCOM INC$26.8M4.00%192,932CommonSOLE
45258D105IMCRIMMUNOCORE HLDGS PLC$25.7M3.84%394,674CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$25.2M3.78%379,803CommonSOLE
92532F100VRTXVERTEX PHARMACEUTICALS INC$24.6M3.68%58,832CommonSOLE
604749101MIRMMIRUM PHARMACEUTICALS INC$24.1M3.60%958,654CommonSOLE
G1110E107BHVNBIOHAVEN LTD$23.6M3.54%432,342CommonSOLE
501147102KRYSKRYSTAL BIOTECH INC$23.3M3.48%130,850CommonSOLE
04351P101ASNDUSDASCENDIS PHARMA A/S$22.9M3.43%151,587CommonSOLE
89377M109TMDXTRANSMEDICS GROUP INC$22.0M3.29%297,377CommonSOLE
23954D109DAWNGBXDAY ONE BIOPHARMACEUTICALS I$21.8M3.26%1,318,207CommonSOLE
670703107NUVLNUVALENT INC$20.0M2.99%265,897CommonSOLE
462222100IONSIONIS PHARMACEUTICALS INC$18.3M2.73%421,487CommonSOLE
92243G108PCVXVAXCYTE INC$17.8M2.66%260,281CommonSOLE
00773J202SYRESPYRE THERAPEUTICS INC$17.6M2.64%464,435CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$17.5M2.61%397,782CommonSOLE
45258J102IMVTIMMUNOVANT INC$16.6M2.48%512,893CommonSOLE
254604101IRONDISC MEDICINE INC$15.7M2.35%252,673CommonSOLE
925050106VRNAVERONA PHARMA PLC$15.7M2.34%973,130CommonSOLE
68622P109ORICORIC PHARMACEUTICALS INC$15.1M2.26%1,097,571CommonSOLE
46116X101ITCIEURINTRA-CELLULAR THERAPIES INC$14.3M2.14%206,707CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$14.0M2.09%1,179,420CommonSOLE
02081G201ATECALPHATEC HLDGS INC$13.7M2.04%990,618CommonSOLE
52490G102LEGNLEGEND BIOTECH CORP$12.8M1.92%228,251CommonSOLE
30233G209EYPTEYEPOINT PHARMACEUTICALS INC$12.1M1.81%585,447CommonSOLE
92686J106VKTXVIKING THERAPEUTICS INC$10.5M1.57%128,064CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$6.8M1.01%250,870CommonSOLE
90240B106TYRATYRA BIOSCIENCES INC$6.3M0.94%381,210CommonSOLE
92337R101VERAVERA THERAPEUTICS INC$5.1M0.76%118,260CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.